Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)
Globe Newswire•19/11/2026•07:30 ET
0
Key Highlights
- ➤Palvella (PVLA) announces QTORIN™ docetaxel for extramammary Paget’s disease
- ➤QTORIN™ docetaxel targets estimated U.S. EMPD population exceeding 10,000 patients
- ➤Palvella initiates IND-enabling activities for QTORIN™ docetaxel
- ➤FDA meeting planned for first half of 2027 before Phase 2 initiation
- ➤QTORIN™ docetaxel could become the first FDA-approved EMPD therapy
Expert Statements
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“Our objective is to bring meaningful innovation, and ultimately the first FDA-approved therapy, to the EMPD community.”
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“Today, patients with EMPD often face repeated, disfiguring surgeries and high rates of disease recurrence.”
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in metastatic EMPD, with the potential to transform the treatment paradigm to first-line, localized topical therapy.”
Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics
“EMPD has the hallmark characteristics of an opportunity where Palvella can make a significant impact: a serious, rare skin disease with no FDA-approved therapies, a compelling scientific rationale, and a clear path toward potentially delivering the first FDA-approved therapy.”
EMPD is a serious, rare, and life-threatening genital and perianal skin cancer
QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment paradigm to first-line, localized topical therapy
Get started
Create a free account to read the full story.
